Hinge Bio Collaborates with Kyorin Pharmaceutical to Advance HB2198 in Japan for Autoimmune Diseases

Shots: Hinge Bio & Kyorin have entered into a collaboration & license agreement to develop HB2198 in Japan for various autoimmune diseases, starting with systemic lupus erythematosus (SLE), which is expected to enter trials by H2’25 As per the deal, Hinge will lead global HB2198 development & receive $10M upfront, ~$95M in SLE milestones, plus additional…

ByRidhi Rastogi15 hours ago

NEWS

BeiGene Reports the US FDA approval for Tevimbra + CT as a 1L Treatment of Advanced ESCC

Shots: The US FDA approved Tevimbra (tislelizumab-jsgr) + Pt containing CT as 1L treatment in unresectable or metastatic esophageal squamous cell carcinoma (ESCC) adults whose tumors express PD-L1 (≥1) The approval was based on the P-III (RATIONALE-306) study (n=649) evaluating Tevimbra + CT vs. PBO + CT in unresectable, locally advanced recurrent, or metastatic…

ByadminMarch 5, 2025

NEWS

KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223

Shots: KYORIN and Novartis entered into a global license agreement for KRP-M223 and its back-up compounds discovered by KYORIN As per the agreement, Novartis gets an exclusive global license to develop, manufacture, and commercialize KRP-M223, where KYORIN retains an option to commercialize and manufacture product for the Japanese market, with Novartis retaining an option to co-promote…

ByRidhi RastogiMarch 4, 2025

Hinge Bio Collaborates with Kyorin Pharmaceutical to Advance HB2198 in Japan for Autoimmune Diseases

BeiGene Reports the US FDA approval for Tevimbra + CT as a 1L Treatment of Advanced ESCC

KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223

Contact US

OUR INFORMATION

FOLLOW US